Table 2.
Univariate analyses among patients who underwent a 8/8 matched unrelated donor (URD) or HLA identical sibling donor (Sib) myeloablative stem cell transplantation for AML, ALL, and CML between 1995 and 2004
| Disease status* |
TRM† |
Relapse† |
LFS† |
||||||
|---|---|---|---|---|---|---|---|---|---|
| (N: Sib/URD) | Sib | URD | P | Sib | URD | P | Sib | URD | P |
| AML | |||||||||
| Early (760/118) | 24 (20-27) | 40 (31-50) | .001 | 15 (13-18) | 22 (15-30) | .1 | 61 (57-65) | 38 (28-48) | < .001 |
| Intermediate (180/88) | 30 (23-37) | 39 (28-50) | .18 | 22 (16-29) | 21 (13-30) | .8 | 48 (40-56) | 41 (30-52) | .3 |
| Advanced (294/129) | 31 (25-36) | 44 (35-53) | .01 | 46 (40-52) | 43 (34-51) | .6 | 23 (18-29) | 13 (8-20) | .01 |
| ALL | |||||||||
| Early (271/62) | 31 (25-37) | 43 (30-57) | .09 | 23 (18-29) | 15 (7-25) | .13 | 46 (39-53) | 42 (29-55) | .6 |
| Intermediate (111/61) | 41 (32-51) | 40 (27-53) | .9 | 32 (24-42) | 36 (24-48) | .7 | 27 (18-36) | 24 (14-37) | .8 |
| Advanced (88/64) | 38 (28-48) | 48 (35-60) | .2 | 52 (42-63) | 48 (35-60) | .6 | 10 (4-18) | 5 (1-12) | .2 |
| CML | |||||||||
| Early (1122/281) | 30 (27-33) | 37 (31-43) | .02 | 10 (8-12) | 10 (6-13) | .81 | 60 (57-63) | 54 (48-60) | .06 |
| Intermediate (169/87) | 40 (32-48) | 47 (36-58) | .3 | 27 (20-34) | 21 (13-30) | .3 | 34 (26-42) | 32 (23-43) | .8 |
| Advanced (47/27) | 32 (19-47) | 67 (48-83) | .003 | 43 (29-58) | 33 (17-52) | .4 | 25 (13-39) | 0 | < .001 |
Differences between TRM and LFS but no difference in relapse between the 2 groups in univariate analysis are shown. Analysis is stratified by disease and disease stage; 5-year probability for treatment related mortality (TRM), relapse, and leukemia-free survival (LFS) is given (95% confidence interval).
N: Sib/URD indicates number of patients in HLA-identical sibling/unrelated donor groups; URD, unrelated donor; Sib, HLA-identical sibling; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; and CML, chronic myeloid leukemia.
Disease status is categorized as follows: early includes AML and ALL in CR1 or CML in first chronic phase; intermediate includes AML and ALL in ≥ CR2 or CML in accelerated phase or ≥ second chronic phase; and advanced includes AML and ALL with relapse or primary induction failure or CML in blast crisis.
Percentage of 5-year probability.